Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

<h3>Background</h3><p dir="ltr">There is limited evidence in the literature on the long-term effectiveness and cost-effectiveness of treatments for Acute Severe Ulcerative Colitis (ASUC). The study aimed to perform decision analytic model-based long-term cost-utility anal...

Full description

Saved in:

Bibliographic Details
Main Author:	Mohammed Fasihul Alam (6832217) (author)
Other Authors:	Mirella Longo (6833627) (author), David Cohen (133780) (author), Sam Groves (5234345) (author), Laith Alrubaiy (15267632) (author), Hayley A. Hutchings (14085594) (author), Alan Watkins (432126) (author), Shaji Sebastain (15267635) (author), John G. Williams (111321) (author)
Published:	2023
Subjects:	Human society Policy and administration Ulcerative colitis Infiximab Ciclosporin Cost-efectiveness Decision tree Markov model
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

Similar Items